ABBV-744 CLINICAL TRIAL PHASE 2 DATA THINGS TO KNOW BEFORE YOU BUY

In Segment C, participants will acquire ABBV-744 and oral navitoclax. In Phase D, members will acquire ABBV-744 and ruxolitinib. Individuals will obtain treatment until eventually condition progression or maybe the participants are not able to tolerate the study drugs.For all circulation cytometry experiments, 10,000 cells for each replicate were a